Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

HMPL-013

Known as: VEGFR-1/2/3 Inhibitor HMPL-013 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
ABSTRACT Introduction: Anti-angiogenetic agents are currently the most commonly used drugs for the treatment of colorectal cancer… Expand
Is this relevant?
2017
2017
PurposeFruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
PurposeFruquintinib (HMPL-013) is a novel oral small molecule compound that selectively inhibits vascular endothelial growth… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2014
2014
AbstractPurpose This study evaluated the preclinical pharmacokinetics (PK) and disposition of Fruquintinib (HMPL-013), a small… Expand
  • figure 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
2014
2014
VEGF/VEGFR signal axis has been proven to be an important target for development of novel cancer therapies. One challenging… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?